{"nctId":"NCT01270347","briefTitle":"Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients","startDateStruct":{"date":"2011-01"},"conditions":["Cystic Fibrosis"],"count":282,"armGroups":[{"label":"Aeroquin","type":"EXPERIMENTAL","interventionNames":["Drug: MP-376 (Levofloxacin Solution for Inhalation)"]},{"label":"TIS","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TIS (Tobramycin Inhalation Solution)"]}],"interventions":[{"name":"MP-376 (Levofloxacin Solution for Inhalation)","otherNames":["(Aeroquin, Levofloxacin solution for Inhalation)"]},{"name":"TIS (Tobramycin Inhalation Solution)","otherNames":["TOBI"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria (selected):\n\n* \\> 12 years of age\n* Confirmed Diagnosis of Cystic Fibrosis\n* Positive sputum culture for P. aeruginosa within the past 12 months\n* Patients are able to elicit an FEV1 \\>/= 25% but \\</= 85% of predicted value at screening\n* Have received at least 3 courses of inhaled tobramycin over the preceding 12 months\n* Clinically stable with no changes in health status within the last 28 days\n* Able to reproducibly produce sputum and perform spirometry\n\nExclusion Criteria (selected):\n\n* Use of any nebulized or systemic antibiotics within 28 days prior to baseline\n* History of hypersensitivity to fluoroquinolones or inhaled or systemic aminoglycosides including tobramycin or any excipients\n* Evidence of acute upper within 10 days or lower respiratory infections within 28 days prior to dosing\n* CrCl \\< 20 at Screening\n* History of lung transplantation\n\nExtension Portion of the Study: Patients enrolled in Mpex 209 are permitted to participate in the open label extension as long as they complete Visit 7 (Day 168), provide informed consent for participation in the open label extension of in the study and are clinically stable, as assessed by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"An AE was defined as any unfavorable or unintended sign, symptom, or disease temporally associated with the use of a Study Drug, whether or not considered related to the Study Drug.\n\nAn AE could potentially be a new disease, any untoward event, or an exacerbation of a pre-existing condition. AEs included, but were not limited to:\n\nAny symptom not previously reported by the patient (medical history) An exacerbation of a pre-existing illness An increase in frequency or intensity of a pre-existing episodic event or condition A condition first detected or diagnosed after Study Drug administration even though the condition may have been present before the start of the study Overdose of Study Drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"180","spread":null}]}]}]},{"type":"PRIMARY","title":"Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (FEV1)","description":"FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer. Least squares (LS) mean and standard error (SE) were determined from an analysis of covariance model with terms for treatment, region (US, non-US), and age (12 to 18 years, \\> 18 years), and Baseline FEV1 (\\< 55%, . 55%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"1.262"},{"groupId":"OG001","value":"2.24","spread":"1.019"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Average Expired Flow Over the Middle Half of The FVC Maneuver (FEF25-75)","description":"LSMean and SE were determined from an ANCOVA model with terms for treatment, region (US, non-US), age (12-18 years, \\>18 years), baseline FEV1 (\\<55%, \\>=55%), and baseline as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.705","spread":"8.8115"},{"groupId":"OG001","value":"9.673","spread":"2.2691"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Forced Vital Capacity (FVC)","description":"LSMean and SE were determined from an ANCOVA model with terms for treatment, region (US, non-US), age (12-18 years, \\>18 years), baseline FEV1 (\\<55%, \\>=55%), and baseline as a covariate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.152","spread":"0.9191"},{"groupId":"OG001","value":"0.417","spread":"0.7441"}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Each Category of Relative Change in Percent Predicted FEV1","description":"FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Each Category of Percent Change From Baseline in FEV1","description":"FEV1 was the volume of air exhaled in first second of a forced expiration as measured by spirometer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pseudomonas Aeruginosa Sputum Density","description":"Pseudomonas aeruginosa density was measured as log10 colony-forming units \\[CFU\\] per gram sputum.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.19","spread":"0.243"},{"groupId":"OG001","value":"-0.75","spread":"0.196"}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Each Category of Change From Baseline in Pseudomonas Aeruginosa Sputum Density","description":"Pseudomonas aeruginosa density was measured as log10 colony-forming units \\[CFU\\] per gram sputum.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R)","description":"The Cystic Fibrosis Questionnaire (CFQ-R) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents and adults with cystic fibrosis (CF). Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"1.576"},{"groupId":"OG001","value":"1.88","spread":"1.278"}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Each Category of Change From Baseline in the Respiratory Domain of CFQ-R","description":"The Cystic Fibrosis Questionnaire (CFQ-R) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents and adults with cystic fibrosis (CF). Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":90},"commonTop":["Disease progression","Cough","Sputum increased","Respiratory tract congestion","Weight decreased"]}}}